Cover Image

Benefit of patients with an early and progressed state of hepatocellular carcinoma treated with drug-eluting beads

Aim: To evaluate drug-eluting beads (DEB) for transarterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) A to D suffering from hepatocellular carcinoma. Material and Methods: The progression-free interval (PFI), survival and laboratory findings of 46 patients were r...

Full description

Saved in:
Bibliographic Details
Main Authors: Rathmann, Nils-Andreas (Author) , Sadick, Maliha (Author) , Rathmann, Björn (Author) , Kostrzewa, Michael (Author) , Weiß, Christel (Author) , Schönberg, Stefan (Author) , Diehl, Steffen J. (Author) , Antoni, Christoph Helmer (Author)
Format: Article (Journal)
Language:English
Published: September-October 2016
In: In vivo
Year: 2016, Volume: 30, Issue: 5, Pages: 707-712
ISSN:1791-7549
Online Access:Verlag, Volltext: http://iv.iiarjournals.org/content/30/5/707
Get full text
Author Notes:Nils Rathmann, Maliha Sadick, Bjoern Rathmann, Michael Kostrzewa, Christel Weiss, Stefan O. Schoenberg, Steffen J. Diehl and Christoph Antoni
Description
Summary:Aim: To evaluate drug-eluting beads (DEB) for transarterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) A to D suffering from hepatocellular carcinoma. Material and Methods: The progression-free interval (PFI), survival and laboratory findings of 46 patients were retrospectively analyzed after DEB TACE. Results: The mean survival interval was 16.93 months. The BCLC A/B group had significantly (p=0.01) longer survival compared to C/D: 20.44 and 10.36 months. Mean PFI was 10.75 months with a significantly (p=0.002) longer PFI of the BCLC A/B group (12.71 months) compared to BCLC C/D (3.91 months). In terms of possible adverse events (AEs) significant changes (p<0.05) were observed in cholinesterase, white blood cells, alkaline phosphatase and C-reactive protein. Conclusion: Mean survival and PFI results in the BCLC A/B patient group were comparable to historical controls. In addition, the results suggest that patients with BCLC stage C/D also benefited from DEB TACE.
Item Description:Gesehen am 14.01.2019
Physical Description:Online Resource
ISSN:1791-7549

Similar Items